Avenda Health has announced that its AI healthcare software can detect prostate cancer with greater accuracy than traditional methods employed by doctors. A recent study involving ten physicians who assessed 50 prostate cancer cases each demonstrated that Avenda’s Unfold AI software achieved an accuracy rate of 84.7%, compared to the manual detection accuracy rates of physicians, which ranged from 67.2% to 75.9%.
Conducted in collaboration with UCLA Health and published in the Journal of Urology, the research also highlighted that AI-assisted cancer contouring predictions were 45 times more accurate and consistent. Shyam Natarajan, assistant adjunct professor of urology, surgery, and bioengineering at UCLA and senior author of the study, stated that using AI made doctors both more accurate and consistent in their assessments.
Doctors typically rely on MRIs to determine tumor sizes; however, Dr. Wayne Brisbane, an assistant professor of urology at UCLA’s David Geffen School of Medicine, noted that some tumors are difficult to detect through MRIs. He emphasized that AI technology fills this gap effectively.
According to Brisbane, integrating AI into cancer treatment may promote more effective and personalized patient care, facilitating treatment plans that are closely tailored to individual requirements. He added that AI could exceed human capabilities in this context.
Dr. Shyam Natarajan, CEO of Avenda Health, expressed enthusiasm about the validation of their innovation through research and its recognition by the American Medical Association (AMA).
The American Cancer Society estimates that approximately 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and 1 in 44 men will succumb to the illness. In the United States, there are projected to be 299,010 new prostate cancer cases this year, with 35,250 expected fatalities.